Andrew Slee
Chief Operating Officer at PROTAGENIC THERAPEUTICS, INC.
Net worth: - $ as of 2024-04-29
Profile
Dr. Andrew Slee is a Chief Operating Officer at Protagenic Therapeutics, Inc. Dr. Slee was previously employed as a Founder by Vivisource Laboratories, Inc., a Vice President-Pharmacology & Development by SelectX Pharmaceuticals, Inc., a Principal by DuPont Merck Pharmaceutical Co., a Principal by DuPont Pharmaceuticals Co., a Vice President-Pharmacology by Enanta Pharmaceuticals, Inc., and a Senior Director-Preclinical Pharmacology by Safety Pharmacology Society.
He received his undergraduate degree from Syracuse University.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
| 2024-03-31 | 0 ( -.--% ) | - $ | 2024-04-29 |
Andrew Slee active positions
| Companies | Position | Start |
|---|---|---|
| PROTAGENIC THERAPEUTICS, INC. | Chief Operating Officer | 2016-03-31 |
Former positions of Andrew Slee
| Companies | Position | End |
|---|---|---|
| Vivisource Laboratories, Inc. | Founder | 2013-09-30 |
SelectX Pharmaceuticals, Inc.
 SelectX Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology SelectX Pharmaceuticals, Inc. engages in the discovery and development of aminoglycoside therapeutics for unmet medical needs. Its advanced program, development candidate SXP2523, is a next generation aminoglycoside antibiotic for drug resistant gram-negative hospital-acquired infections (HAIs); SXP2523 possesses broad spectrum coverage with potency against Pseudomonas, Klebsiella, Acinetobacter, E. coli, and Staphylococcus. The company was founded by Michael G. Chaparian and Charles R. Cantor in 2002 and is headquartered in Boston, MA. | Corporate Officer/Principal | - |
| ENANTA PHARMACEUTICALS, INC. | Corporate Officer/Principal | - |
DuPont Merck Pharmaceutical Co.
 DuPont Merck Pharmaceutical Co. Pharmaceuticals: MajorHealth Technology Part of Corteva, Inc., DuPont Merck Pharmaceutical Co. is a company that makes pharmaceuticals and drugs. The company is based in Wilmington, DE. DuPont Merck Pharmaceutical was acquired by EIDP, Inc., a subsidiary of Corteva, Inc. from Merck & Co., Inc. on July 01, 1998 for $2,600 million. | Corporate Officer/Principal | - |
DuPont Pharmaceuticals Co.
 DuPont Pharmaceuticals Co. Pharmaceuticals: MajorHealth Technology DuPont Pharmaceuticals Co. researches and develops pharmaceuticals and imaging products to treat diseases. It focuses on pharmaceuticals to treat unmet medical needs in the fight against HIV, cardiovascular disease, central nervous system disorders, cancer and arthritis-related disorders. The company is located in Wilmington, DE. | Corporate Officer/Principal | - |
Training of Andrew Slee
| Syracuse University | Undergraduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 2 |
|---|---|
| ENANTA PHARMACEUTICALS, INC. | Health Technology |
| PROTAGENIC THERAPEUTICS, INC. | Health Technology |
| Private companies | 5 |
|---|---|
DuPont Pharmaceuticals Co.
DuPont Pharmaceuticals Co. Pharmaceuticals: MajorHealth Technology DuPont Pharmaceuticals Co. researches and develops pharmaceuticals and imaging products to treat diseases. It focuses on pharmaceuticals to treat unmet medical needs in the fight against HIV, cardiovascular disease, central nervous system disorders, cancer and arthritis-related disorders. The company is located in Wilmington, DE. | Health Technology |
DuPont Merck Pharmaceutical Co.
DuPont Merck Pharmaceutical Co. Pharmaceuticals: MajorHealth Technology Part of Corteva, Inc., DuPont Merck Pharmaceutical Co. is a company that makes pharmaceuticals and drugs. The company is based in Wilmington, DE. DuPont Merck Pharmaceutical was acquired by EIDP, Inc., a subsidiary of Corteva, Inc. from Merck & Co., Inc. on July 01, 1998 for $2,600 million. | Health Technology |
SelectX Pharmaceuticals, Inc.
SelectX Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology SelectX Pharmaceuticals, Inc. engages in the discovery and development of aminoglycoside therapeutics for unmet medical needs. Its advanced program, development candidate SXP2523, is a next generation aminoglycoside antibiotic for drug resistant gram-negative hospital-acquired infections (HAIs); SXP2523 possesses broad spectrum coverage with potency against Pseudomonas, Klebsiella, Acinetobacter, E. coli, and Staphylococcus. The company was founded by Michael G. Chaparian and Charles R. Cantor in 2002 and is headquartered in Boston, MA. | Health Technology |
| Vivisource Laboratories, Inc. | |
| Safety Pharmacology Society |
- Stock Market
- Insiders
- Andrew Slee
